KR101253696B1 - 아밀로이드-관련 질환의 치료용 의약품 또는 식품의 생산을 위한 ｄｈａ 함유 지방산 조성물의 용도 - Google Patents

아밀로이드-관련 질환의 치료용 의약품 또는 식품의 생산을 위한 ｄｈａ 함유 지방산 조성물의 용도 Download PDF

Info

Publication number
KR101253696B1
KR101253696B1 KR20077019198A KR20077019198A KR101253696B1 KR 101253696 B1 KR101253696 B1 KR 101253696B1 KR 20077019198 A KR20077019198 A KR 20077019198A KR 20077019198 A KR20077019198 A KR 20077019198A KR 101253696 B1 KR101253696 B1 KR 101253696B1
Authority
KR
South Korea
Prior art keywords
dha
food
epa
fatty acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR20077019198A
Other languages
English (en)
Korean (ko)
Other versions
KR20070104917A (ko
Inventor
모르텐 브라인
크누트 슬레텐
토르스텐스도터 구닐라 웨스터마크
페르 올로프 웨스터마크
Original Assignee
프로노바 바이오파마 너지 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로노바 바이오파마 너지 에이에스 filed Critical 프로노바 바이오파마 너지 에이에스
Publication of KR20070104917A publication Critical patent/KR20070104917A/ko
Application granted granted Critical
Publication of KR101253696B1 publication Critical patent/KR101253696B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
KR20077019198A 2005-01-24 2007-08-22 아밀로이드-관련 질환의 치료용 의약품 또는 식품의 생산을 위한 ｄｈａ 함유 지방산 조성물의 용도 Expired - Fee Related KR101253696B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64560405P 2005-01-24 2005-01-24
SE0500174-8 2005-01-24
SE0500174 2005-01-24
US60/645,604 2005-01-24

Publications (2)

Publication Number Publication Date
KR20070104917A KR20070104917A (ko) 2007-10-29
KR101253696B1 true KR101253696B1 (ko) 2013-04-12

Family

ID=36692011

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20077019198A Expired - Fee Related KR101253696B1 (ko) 2005-01-24 2007-08-22 아밀로이드-관련 질환의 치료용 의약품 또는 식품의 생산을 위한 ｄｈａ 함유 지방산 조성물의 용도

Country Status (7)

Country Link
US (2) US20090054523A1 (enExample)
EP (1) EP1845999A4 (enExample)
JP (1) JP5503846B2 (enExample)
KR (1) KR101253696B1 (enExample)
CA (1) CA2594781A1 (enExample)
NO (1) NO343234B1 (enExample)
WO (1) WO2006077495A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022014824A1 (ko) * 2020-07-17 2022-01-20 대봉엘에스 주식회사 불포화 지방산을 특정 함량으로 포함하는 유지 조성물 및 이의 용도

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP3263101A1 (en) 2005-12-21 2018-01-03 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
KR100879816B1 (ko) 2007-05-31 2009-01-22 학교법인 일송학원 꽁치류의 가수분해물을 포함하는 허혈성 뇌혈관질환 예방또는 개선용 조성물
PT2374452T (pt) * 2008-12-05 2019-10-31 Ajinomoto Kk Composição de nutrientes
CN108324706A (zh) * 2009-02-02 2018-07-27 帝斯曼知识产权资产有限公司 改善认知功能和降低心率的方法
US9532963B2 (en) * 2009-03-09 2017-01-03 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
US20100239660A1 (en) * 2009-03-19 2010-09-23 Doughman Scott D Product and use of omega-3s matching human tissue ratios for treatment of inflammatory and other conditions
US8124574B2 (en) 2009-10-12 2012-02-28 Conopco, Inc. Mild, foaming liquid cleansers comprising low levels of fatty isethionate product and low total fatty acid and/or fatty acid soap content
US8105994B2 (en) 2010-03-31 2012-01-31 Conopco, Inc. Personal wash cleanser comprising defined alkanoyl compounds, defined fatty acyl isethionate surfactant product and skin or hair benefit agent delivered in flocs upon dilution
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
EP2846779A4 (en) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511533A (ja) * 1993-06-09 1996-12-03 マーテック・バイオサイエンスィズ・コーポレーション 神経学的障害の治療に有用な方法および医薬用組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07268385A (ja) * 1994-03-31 1995-10-17 Snow Brand Milk Prod Co Ltd 魚臭が低減されたカツオおよび／またはマグロ油
JPH09511533A (ja) * 1994-09-19 1997-11-18 ザ、プロクター、エンド、ギャンブル、カンパニー 顆粒状漂白組成物
JPH08143454A (ja) * 1994-11-17 1996-06-04 Kanagawa Kagaku Kenkyusho:Kk 神経成長因子産生増強剤
EP0831805A1 (en) * 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6395778B1 (en) * 2000-01-11 2002-05-28 Omegatech, Inc. Process for making an enriched mixture of polyunsaturated fatty acid esters
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
CN1380058A (zh) * 2001-04-10 2002-11-20 上海体育运动技术学院 用于促进人体自身epa、dha合成的药物
US20030077342A1 (en) * 2001-10-09 2003-04-24 Maf Group, Llc Anti-inflammatory complex containing eicosapentaenoic acid
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08511533A (ja) * 1993-06-09 1996-12-03 マーテック・バイオサイエンスィズ・コーポレーション 神経学的障害の治療に有用な方法および医薬用組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022014824A1 (ko) * 2020-07-17 2022-01-20 대봉엘에스 주식회사 불포화 지방산을 특정 함량으로 포함하는 유지 조성물 및 이의 용도

Also Published As

Publication number Publication date
EP1845999A1 (en) 2007-10-24
NO20074318L (no) 2007-10-24
WO2006077495A1 (en) 2006-07-27
KR20070104917A (ko) 2007-10-29
CA2594781A1 (en) 2006-07-27
EP1845999A4 (en) 2010-09-22
JP2008528475A (ja) 2008-07-31
US20090054523A1 (en) 2009-02-26
JP5503846B2 (ja) 2014-05-28
NO343234B1 (no) 2018-12-17
US20120277317A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
US8609726B2 (en) Fatty acid composition for treatment of Alzheimer's disease and cognitive dysfunction
Altinoz et al. PPAR-δ and erucic acid in multiple sclerosis and Alzheimer's disease. Likely benefits in terms of immunity and metabolism
US20120277317A1 (en) Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases
Zhou et al. Mechanisms of DHA-enriched phospholipids in improving cognitive deficits in aged SAMP8 mice with high-fat diet
JP6506206B2 (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
Huang et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury
JP5363152B2 (ja) グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
JP3008213B2 (ja) 医薬組成物
RU2513995C2 (ru) Применение 2-гидроксипроизводных полиненасыщенных жирных кислот в качестве лекарственных препаратов
RU2272620C2 (ru) Способы снижения пролиферации клеток на основе (3r,4r)△8 - тетрагидроканнабинол-11-оновых кислот (кислот из конопли)
JPH07502491A (ja) 皮膚疾患の治療に対して静脈的に投与される薬剤を調整するためのエマルジョンの使用
US8461141B2 (en) Preventive or therapeutic drug for Alzheimer-type dementia
Di Biase et al. Eicosapentaenoic acid pre-treatment reduces biochemical changes induced in total brain and myelin of weanling Wistar rats by cuprizone feeding
JP2574354B2 (ja) 脂肪酸含有成分およびサイクロスポリンよりなる腎毒性の減少した組成物
KR20140057485A (ko) 인지력 감퇴를 위한 의료식품
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
US20120083533A1 (en) Use of amides of mono- and dicarboxylic acids in the treatment of renal diseases
JP2023547479A (ja) 疾患の治療におけるヒト血清アルブミンの使用
JPH10505614A (ja) ホスホグリセロエーテルをベースとした新規組成物と、神経変性疾患の治療におけるその利用
CN101001620B (zh) α-酮基戊二酸和相关化合物用于降低血脂的用途
US20220249420A1 (en) Monounsaturated fatty acid composition and use for treating fatty liver disease
WO2023037375A1 (en) A self-emulsifying drug delivery system (sedds) of punicic acid combined with neuroprotective natural products to delay onset, prevent, or reverse neurodegenerative disease
Baldessarini et al. Fatty acid derivatives of clozapine: prolonged antidopaminergic activity of docosahexaenoylclozapine in the rat
JP3947322B2 (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品
Seniuk Coenzyme Q10 effects in migraine, Parkinson's disease and Alzheimer’s disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160324

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180319

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190318

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200406

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200406